Moleculin Biotech Inc. (MBRX)
0.95
-0.02 (-2.42%)
At close: Apr 01, 2025, 3:59 PM
0.93
-2.74%
Pre-market: Apr 02, 2025, 08:37 AM EDT
-2.42% (1D)
| Bid | 0.92 |
| Market Cap | 13.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -6.32 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.31 |
| Analyst | Buy |
| Ask | 0.96 |
| Volume | 347,832 |
| Avg. Volume (20D) | 5,790,186 |
| Open | 0.97 |
| Previous Close | 0.97 |
| Day's Range | 0.93 - 1.02 |
| 52-Week Range | 0.40 - 5.91 |
| Beta | 1.94 |
About MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 17
Stock Exchange NASDAQ
Ticker Symbol MBRX
Website https://www.moleculin.com
Analyst Forecast
According to 3 analyst ratings, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 740.25% from the latest price.
Stock Forecasts1 month ago
+202.38%
Moleculin Biotech shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
+14.72%
Moleculin Biotech shares are trading higher after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model which demonstrated significant activity.
